About us

Delivering life-changing treatments to cancer patients

Autolus is a CAR T cell therapy company. We are applying our extensive programing capabilities to develop advanced autologous T cell therapies that have the potential to deliver life-changing benefits to cancer patients

Company highlights

Pivotal program

Obe-cel data expected in 2022

Clinical-stage pipeline

Programs in hematological and solid tumor indications

Broad technology base with modular programing approach

Strong intellectual property position
95+ patent families

Manufacturing process

Fully enclosed, semi-automated commercially enabled, economical

Our purpose

Autolus strives to develop best-in-class therapies that offer life-changing benefits for cancer patients

Learn more

Our history

Autolus is founded on advanced cell programming technology pioneered by Dr Martin Pule and was spun-out from University College London in 2014. Since its inception, the company has undergone rapid growth, systematically adding the capabilities and capital required to manufacture, develop and commercialise its programmed T cell product candidates.

Read more


Our team includes pioneers in T cell therapies and leaders in cancer immunotherapies who are committed to the development and delivery of novel medicines that offer life-changing benefits for cancer patients

Learn more

Our partners

Autolus collaborates with leading academic institutions and industry partners to develop and deliver immunotherapies to patients

Learn more

Culture and values

Our team is pushing the boundaries of cancer therapy to deliver life-changing treatments to patients. Our employees enjoy a flexible, diverse, and dynamic working environment which actively promotes creativity, leadership and teamwork.

Find out more